Objective To compare the prevalence of factor V Leiden (FVL) and prothrombin (PT) G20210A mutations in Portuguese women with unexplained recurrent miscarriage (RM) and a control group of parous women. Materials and methods FVL and PT G20210A analysis were carried out in 100 women with three or more consecutive miscarriages and 100 controls with no history of pregnancy losses. Secondary analysis was made regarding gestational age at miscarriage (embryonic and fetal losses). Results Overall, the prevalence of FVL and PT G20210A was similar in women with RM (5 and 3%) compared with controls (5 and 1%) OR 1.36 (CI 95% 0.45-4.08). In RM embryonic subgroup, PT G20210A was observed in 1.3% of women and FVL prevalence (2.6%) was inclusively lesser than that of controls. Both polymorphisms were more prevalent in women with fetal losses than in controls, although statistical significance was not reached due to the small size of the [10 weeks' subgroup. Conclusion These data indicate that neither FVL nor PT G20210A is associated with RM prior to 10 weeks of gestation. Therefore, its screening is not indicated as an initial approach in Portuguese women with embryonic RM and negative personal thromboembolic history.
Introduction
One per cent of women in the reproductive age group experience recurrent miscarriage (RM), three or more clinically recognized pregnancy losses before 22nd gestational week [1] [2] [3] . RM is one of the most disturbing women's health issues and several medical factors (chromosomal, anatomic, autoimmune, and metabolic disorders) have been reported as possible causes [4] [5] [6] [7] [8] . However, after standard investigations, up to 50% of these cases remain unexplained [2, 9, 10] .
Thrombophilia is the main risk factor for maternal thromboembolism. Data accumulated over the past two decades have established a clear association between antiphospholipid syndrome (APS), an acquired thrombophilic state, and RM [11] [12] [13] [14] [15] . Recent investigations have focused on a higher prevalence of certain inherited thrombophilias, such as factor V Leiden (FVL) and prothrombin (PT) G20210A mutations, in women with unexplained recurrent pregnancy losses [16] [17] [18] [19] [20] [21] . Nevertheless, these reports have produced conflicting results [22] [23] [24] [25] and this heterogeneity is reflected in existing meta-analyses [17, 20, 26, 27] .
The relative preponderance of particular type of thrombophilic gene may depend on the patient's ethnic origin, altering the relative importance of thrombophilic marker as a cause of RM [28] . In 1994, it was first described that FVL is the genetic risk factor for thrombosis more prevalent in humans [29] . This polymorphism is relatively common among the Caucasian population, ranging from 1 to 10% in different geographic regions [26] [27] [28] [29] [30] . PT G20210A, the second most frequently inherited thrombophilia, is present in 1 to 3% of the Europeans [31] . In Mediterranean countries, prevalence of 5 and 2%, respectively for these mutations were described [32] .
Together with ethnicity, other confounding factors, such as the specification of the gestational age of pregnancy losses and the inclusion of patients with known causes of RM, have led to heterogeneous results in existing studies, and point to the need for more uniform research before inclusion of these exams in RM etiological investigation. However, two recent studies conducted in the USA and in the UK, exploring practice patterns of obstetricians, showed that a large proportion of clinicians include heritable thrombophilia in RM initial investigation. The majority (70-80%) of the respondents tests patients routinely for FVL and 50% for PT G20210A. About 80% of the women who tests positive start antithrombotic therapy with AAS and/or heparin in subsequent pregnancies [33, 34] .
The prevalence of FVL and PT G20210A in Portuguese women with RM has not yet been studied. Therefore, the purpose of this study was to assess the association between these two hereditary thrombophilias and RM in our population.
Materials and methods

Participants
The study population comprised 100 consecutive women with unexplained RM, referred for evaluation at the Recurrent Miscarriage Clinic at Maternidade Dr. Alfredo da Costa, Lisbon, and 100 matched controls.
In the study group, eligibility criteria were the existence of three or more consecutive pregnancy losses before 22nd week, regardless of a previous live birth. Patients were included in the study only if the conventional etiological factors for RM (parental chromosomal abnormalities, uterine structural abnormalities or APS) were found to be normal. Women under the age of 18 or above 40 years were excluded.
The control group consisted of 100 age-matched women with at least one child alive and without history of pregnancy losses or other gestational complication. The control group also matched to the ethnic origin of the patients.
All women with a history of thromboembolic events were excluded from this study ( Table 1) .
The average number of losses of the RM group was 3.43 per woman (min 3-max 6). The majority (77%) had suffered embryonic losses (\10th gestational weeks) and 23 had at least one fetal loss (11-22 weeks). Sixty-one were nulliparous (primary miscarriage) and the remaining 39 had at least one previous live birth. Controls had an average of 1.6 children (DP = 0.67; min 1-max 3). Ninetythree percent of women in each group were Caucasian. Women with RM were slightly older (M = 32 years) than those of the control group (M = 30.9 years), although this difference was not significant (t = -1.698; df = 198; p = 0.091).
The demographic details and outcome of previous pregnancies of these women are shown in Table 2 .
Laboratory procedure Blood samples were collected in sodium citrate from all women and double centrifuged. Platelet-poor plasma obtained was separated, tested for prothrombin time and partial thromboplastin time and frozen at -20°C. After plasma separation, the resulting cells were stored at -20°C. Screening for FVL was made through the resistance to activated protein C (RPCa), using the kit Hemosil Factor V Leiden (APCTM Resistance V), Instrumentation Laboratory, Italy. A cutoff value of 2.1 was considered, and all samples with higher value were considered negative for the presence of FVL. DNA was extracted and isolated through automatic method of solid phase, according to the manufacturer's instructions (EZ1 200 ll blood DNA Kit used with Biorobot EZ1, both of Qiagen, Germany). Molecular diagnosis of FVL and PT G20210A mutations was performed by reverse hybridization of DNA amplification by PCR products using allele-specific oligonucleotide probes (PTH StripAssay kits and FV StripAssay, ViennaLab Diagnostics GmbH, Austria).
Ethics
The study was approved by the Ethical Committee of the Hospital. Informed consent was obtained from each woman.
Statistical analysis
Data were expressed in the form of mean ± SD and percentages as appropriate. To compare the groups on categorical variables, Chi square test (v 2 ) was used and, when the expected frequencies were lesser than five, it was replaced by the likelihood ratio Chi square test (G test), as recommended by Agresti [35] and Ö zdemir and Eyduran [36] . For comparison between the two means, an independent Student's t test was performed. The magnitude of association odds ratio (OR) and their confidence intervals (CI) to 95% were calculated by logistic regression. The statistical analysis was carried out in the program SPSS version 15 (Inc., Chicago, IL), considering a significance level of 5%.
Results
An abnormal thrombophilic genotype was found in a similar percentage (8% vs. 6%) among women with RM and healthy controls (Table 3) . However, the prevalence of FVL was equal among patients and controls (5%); PT G20210A was more frequent in RM women, although this difference was not significant (3% vs. 1%) OR 3.06 (CI 95% 0.31-29.94). There was no detected double carriage of the mutations in our investigated group of women. All heterozygous for FVL occurred in the Caucasian women.
When analyzed separately, carriage of these mutations was found in 3 of 77 women (3.9%) with embryonic losses and in 6% of the controls OR 0.64 (CI 95% 0.15-2.63; p [ 0.05). In this group of women, the prevalence of FVL was inclusively inferior in patients (2.6%) compared to controls (5%) ( Table 3) .
In 5 out of the 23 the women with fetal losses (21.7%) a polymorphism was identified ( Table 3 ). The prevalence of both FVL (13%) and PT G20210A (8.7%) in this subgroup of women was much more pronounced than in the control group (5 and 1%, respectively).
Ethnicity or parity did not influence our results in either embryonic or fetal losses subgroups.
Discussion
In our study, no difference was found in the prevalence of these two polymorphisms among women with RM and a control group of healthy parous women. Similar results have been reported by Dilley et al. [23] Arch Gynecol Obstet (2011) 284:1127-1132 1129 study conducted in 60 women with RM and 92 parous controls. Two prospective multicenter studies, involving each over 4,000 first trimester pregnant women, did not find an increased miscarriage rate in carriers of these mutations [37, 38] . A European prospective research, conducted in women with a previous miscarriage, has also found a similar outcome between subsequent pregnancies of FVL and PT G20210A carriers and noncarriers [22] . However, other studies revealed discordant results and clinicians continue to incorporate these tests in RM investigation protocol [17, 21, 26, 33, 34] . Some methodological aspects such as inclusion in studies of participants with other potential underlying causes of RM, the lack of stratification of cases by women's ethnicity and gestational age of losses, may have impaired the quality of the available data [26] .
in a controlled
RM is a multifactorial entity and the great variation in the strength of this association found in most studies may indicate the presence of additional risk factors. To diminish this type of potential biases, in our research, only cases of unexplained RM were considered.
Gestational age of the losses may also influence the strength of this association. Clinical miscarriage is an entity that covers a wide period of time which extends from the biochemical identification of pregnancy until the 22nd week, and different pathophysiological mechanisms may be responsible for pregnancy loss. For this reason, many authors have chosen to examine separately the impact of hereditary thrombophilia on each trimester of pregnancy. Controlled studies conducted in the European Caucasian women with a history of unexplained RM failed to demonstrate an association between these two polymorphisms and 1st trimester RM [19, 39] . The meta-analyses that have adopted this methodology has also revealed a higher ratio of FLV related losses after the 14th week (OR 2.28) compared with 1st trimester RM (OR 1.6-1.91) [20, 26, 27, 40] .
Factor V plays an important role in cell adhesion, proliferation of smooth muscle and vasculogenesis during embryonic development, and a possible beneficial effect of FVL, due to facilitation in embryonic implantation, had already been suggested by Majerus and Roque et al. [41] [42] [43] . According to this hypothesis, an increase in implantation rate has been reported in pregnancies resulting from intracytoplasmatic sperm injection, in situations where the mother and/or fetus were carriers of FVL [44] . A recent study, conducted by Ivanov et al. [45] in the Caucasian women with unexplained RM, has consolidated these results. These authors found a similar prevalence of FVL (9.6 vs. 7%) in women with embryonic losses and controls OR 1.41 (CI 95% 0.45-4.41). On contrary, in the group of women who suffered losses between 10 and 14 weeks of gestation, the prevalence of FVL (18.6%) was much more pronounced OR 3.05 (CI 95% 1.01-9.38, P = 0.047). Our results are also in line with those of this study, and while among women with embryonic losses FVL prevalence (2.6%) was even lesser than that of controls (5%) OR 0.50 (CI 95% 0.09-2.68), in women with fetal losses this prevalence (13%), though not significant, was substantially higher OR 2.85 (0.63-12.9).
Most of the scientific evidence that associates PT G20210A mutation to pregnancy failure originates in casecontrol studies [24, 25, 46] . These studies, as those carried out on the FLV, are subject to bias and may overstate its impact on obstetric outcome [38] . Nevertheless, in most investigations, this relationship is consistent and, as described for FLV, is weaker with 1st trimester compared with 2nd trimester RM [17, 20, 27] . In the study of Ivanov et al. [45] , the prevalence of PT20210A was higher in women with both embryonic (17%) and fetal (16.9%) losses compared with controls (3%). Our results also showed an increased prevalence of this polymorphism in RM women, particularly patent in those with fetal miscarriages. However, the reduced size of this subgroup of patients (n = 23) does not allow us to establish any secure association.
The main limitation of our investigation relates to the dimension of our population and a larger study might clarify some interpretations.
Conclusions
The impact of heritable thrombophilia on RM remains a controversial issue and recent investigations have sparked the uncertainty about the existence of a causal relationship between these two entities [47] [48] [49] [50] [51] . Our data reinforce the results of previous research and indicate that FVL and PTG20210 are not associated with pregnancy wastage prior to 10 weeks of gestation. Although these polymorphisms were more prevalent in women with fetal losses, overall, our results do not support their screening as an initial approach in the Portuguese women with RM and a negative personal history of thromboembolism.
